Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Eagle Pharmaceuticals Inc EGRX

Healthcare Biotechnology
Eagle Pharmaceuticals, Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial capabilities. The Company is focused on developing medicines that result in improvements in patients' lives. The Company's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (GREY:EGRX)

Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan

GlobeNewswire 2 days ago

Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration

GlobeNewswire November 15, 2024

Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer

GlobeNewswire November 12, 2024

Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan

GlobeNewswire October 31, 2024

INVESTOR ALERT: Rigrodsky Law, P.A. Is Investigating Eagle Pharmaceuticals, Inc. On Behalf of Shareholders

ACCESS Newswire October 22, 2024

Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

GlobeNewswire August 27, 2024

Lifshitz Law PLLC Announces Investigations of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX), Akero Therapeutics, Inc. (NASDAQ: AKRO), Rivian Automotive, Inc. (NASDAQ: RIVN), and QuidelOrtho Corporation (NASDAQ: QDEL)

ACCESS Newswire June 27, 2024

Lifshitz Law PLLC Announces Investigations of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX), Driven Brands Holdings Inc. (NASDAQ:DRVN), Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), and Gristone bio, Inc. (NASDAQ:GRTS)

ACCESS Newswire June 14, 2024

Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

GlobeNewswire May 22, 2024
View More News ››

Opinion & Analysis (GREY:EGRX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (GREY:EGRX)

RE:BNN

Eagle Pharmaceuticals Fiscal Q4 Loss Widens More Than Expected Despite Revenue Beat as Expenses Climb,Dec 2014  doesn't sound...
picassolover - January 6, 2015

BNN

Stock made a BNN guests buy list today
HighteawithIntrepid - January 6, 2015
View more Bullboard ››

Cascadia Minerals Ltd

Cascadia Minerals Ltd

Cascadia is a Canadian junior mining company focused on exploring for copper and gold in the Yukon and British Columbia ...
View More »